Nadolol vs Atenolol — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

beta-Adrenergic Blocker

Nadolol

First FDA approval: 2016-02-23

beta-Adrenergic Blocker

Atenolol

Brand: TENORMIN

First FDA approval: 1992-01-24

Lowest NADACAcquisition cost floor across all NDCs

$0.193Per unit

$0.022Per unit

Average NADACAcross all dosage forms and strengths

$0.258Up to $0.304

$0.028Up to $0.038

Generic manufacturersActive ANDA holders — FDA Orange Book

1030 total ANDAs filed

927 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$21.2MFull year

$77.9MFull year

Part D claims (CY24)Total fills, all strengths

405K121K beneficiaries

9.5M3.0M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$52Per claim, all NDCs

$8Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes10 manufacturers

Yes9 manufacturers